Phase 3 N=253 Olopatadine Hydrochloride Ophthalmic Solution Study in Chinese Subjects
Allergic Conjunctivitis
Primary: Change From Baseline in Worst Ocular Itching Score During the 24 Hours Prior at Day 14 — -2.57; -2.62 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=978 Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Glioblastoma · Gliosarcoma · Supratentorial Glioblastoma
Primary: Overall Survival (OS) — 16.1; 15.7 months — p=0.11
Phase 3 N=484 GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone
Diabetes Mellitus Type 2
Primary: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 — -0.34; -0.90 percentage of hemoglobin — p=<0.0001
Phase 3 N=446 24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine
Type 2 Diabetes Mellitus
Primary: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 — -0.40; -0.71 percentage of hemoglobin — p=<0.0001
Phase 3 N=319 24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years
Type 2 Diabetes Mellitus
Primary: Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than 7% and at Least 5% Weight Loss From Baseline at Week 24 — 12.0; 7.5 percentage of…
Phase 3 N=312 Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)
Human Immunodeficiency Virus (HIV)
Primary: Number of Participants With Early Discontinuation From Randomized Human Immunodeficiency Virus Postexposure Prophylaxis (HIV PEP) — 10; 15 participants — p=0.2434
Phase 3 N=496 GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin
Diabetes Mellitus, Type 2
Primary: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 — -0.38; -0.74 percentage of hemoglobin — p=0.0002
Phase 3 N=639 GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin
Diabetes Mellitus, Type 2
Primary: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 — -0.79; -0.96 percentage of hemoglobin
Phase 3 N=137 Decrease Emergence Agitation and Provide Pain Relief for Children Undergoing Tonsillectomy & Adenoidectomy
Obstructive Sleep Apnea
Primary: Emergence Agitation and Pain — 14; 10; 4; 3 units on a scale — p=.001
Phase 3 N=311 GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)
Diabetes Mellitus, Type 2
Primary: Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24 — 0.11; -0.77 percentage of hemoglobin — p=<0.0001
Phase 3 N=1,200 Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer
Prostate Cancer
Primary: Overall Survival (OS) — 13.4; 14.5 months
Phase 3 N=63 Study of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Japanese Participants With Chronic Hepatitis C (MK-5172-058)
Hepatitis C
Primary: Part 2: Percentage of Treatment-naïve Participants in the Immediate Treatment Arm Achieving Sustained Viral Response at 12 Weeks After The End of All Treatment (SVR12)…
Phase 3 N=77 Efficacy and Safety of Nasal Glucagon for Treatment of Hypoglycemia in Adults
Diabetes Mellitus, Type 1
Primary: Increase in Plasma Glucose Level to >=70mg/dL or an Increase of >=20mg/dL From Glucose Nadir — 98.7; 100 percentage of participants
Phase 3 N=121 Blinded Safety & Efficacy Placebo Controlled Study of Icatibant for Angiotensin Converting Enzyme Inhibitor Induced Angioedema
Angiotensin Converting Enzyme Inhibitor Induced Angioedema
Primary: Time to Meeting Discharge Criteria (TMDC) — 4.03; 4.00 days — p=0.633
Phase 3 N=63 Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia · Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 · Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Primary: Event-Free Survival (EFS) of Patients With Standard-risk Disease Treated With Dasatinib in Combination With Intensified Chemotherapy — 79.8; 83.2; 66.7 Percent probability